Dr Rachel Conyers
Dr Rachel Conyers
Details
Role
Group Leader / Clinical Research Fellow
Group
Cancer Therapies
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s...
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
Top Publications
- Grimshaw, SL, Taylor, NF, Conyers, R, Shields, N. Evaluating the measurement properties and feasibility of physical activity and physical function assessments for children undergoing acute cancer treatment. JSAMS Plus 4: 100065 2024 view publication
- Lange, PW, Turbić, A, Soh, CH, Clayton-Chubb, D, Lim, WK, Conyers, R, Watson, R, Maier, AB. Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo-controlled trial.. J Am Geriatr Soc 72(6) : 1802 -1809 2024 view publication
- Stenta, T, Assis, M, Ayers, K, Tucker, EJ, Halman, A, Gook, D, Sinclair, AH, Elliott, DA, Jayasinghe, Y, Conyers, R. Pharmacogenomic studies of fertility outcomes in pediatric cancer survivors - A systematic review.. Clin Transl Sci 17(6) : e13827 2024 view publication
- Conyers, R, Halman, A, Moore, C, Stenta, T, Felmingham, B, Collier, L, Khatri, D, Spelman, T, Williams, E, Dyas, R, et al. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.. BMJ Open 14(5) : e085115 2024 view publication
- Finney, J, Felmingham, B, Kumar, S, Mahmood, A, Horvath, L, Celermajer, D, Conyers, R. Abstract PO2-20-06: Using the Australian Cardio-Oncology Registry to study long-term cancer therapy related cardiac dysfunction in adult oncology patients – The Chris O’Brien Lifehouse experience. Cancer Research 84(9_Supplement) : po2-20-06-po2-20-06 2024 view publication
Page 1 of 16
Career information
Share //
